ラザベミド
|
- ￥15900 - ￥45800
- 化学名: ラザベミド
- 英語名: LAZABEMIDE
- 別名:N-(2-アミノエチル)-5-クロロ-2-ピリジンカルボアミド;ラザベミド;ラザベミド 水和物;N-(2-アミノエチル)-5-クロロピリジン-2-カルボキサミド
- CAS番号: 103878-84-8
- 分子式: C8H10ClN3O
- 分子量: 199.64
- EINECS:
- MDL Number:MFCD00865419
2物価
選択条件：
ブランド
- Sigma-Aldrich Japan
パッケージ
- 10mg
- 50mg
- 生産者Sigma-Aldrich Japan
- 製品番号SML0042
- 製品説明ラザベミド 水和物 ≥97% (HPLC)
- 英語製品説明Lazabemide hydrate ≥97% (HPLC)
- 包装単位10mg
- 価格￥15900
- 更新しました2024-03-01
- 購入
- 生産者Sigma-Aldrich Japan
- 製品番号SML0042
- 製品説明ラザベミド 水和物 ≥97% (HPLC)
- 英語製品説明Lazabemide hydrate ≥97% (HPLC)
- 包装単位50mg
- 価格￥45800
- 更新しました2023-06-01
- 購入
| 生産者 | 製品番号 | 製品説明 | 包装単位 | 価格 | 更新時間 | 購入 |
|---|---|---|---|---|---|---|
| Sigma-Aldrich Japan | SML0042 | ラザベミド 水和物 ≥97% (HPLC) Lazabemide hydrate ≥97% (HPLC) |
10mg | ￥15900 | 2024-03-01 | 購入 |
| Sigma-Aldrich Japan | SML0042 | ラザベミド 水和物 ≥97% (HPLC) Lazabemide hydrate ≥97% (HPLC) |
50mg | ￥45800 | 2023-06-01 | 購入 |
プロパティ
沸点 :397.4±37.0 °C(Predicted)
比重(密度) :1.286±0.06 g/cm3(Predicted)
貯蔵温度 :room temp
溶解性 :DMSO: ≥22mg/mL
酸解離定数(Pka) :12.90±0.46(Predicted)
外見 :powder
色 :white to tan
InChI :1S/C8H10ClN3O.H2O/c9-6-1-2-7(12-5-6)8(13)11-4-3-10;/h1-2,5H,3-4,10H2,(H,11,13);1H2
InChIKey :JYWYNPKXSLPWGV-UHFFFAOYSA-N
SMILES :O.NCCNC(=O)c1ccc(Cl)cn1
比重(密度) :1.286±0.06 g/cm3(Predicted)
貯蔵温度 :room temp
溶解性 :DMSO: ≥22mg/mL
酸解離定数(Pka) :12.90±0.46(Predicted)
外見 :powder
色 :white to tan
InChI :1S/C8H10ClN3O.H2O/c9-6-1-2-7(12-5-6)8(13)11-4-3-10;/h1-2,5H,3-4,10H2,(H,11,13);1H2
InChIKey :JYWYNPKXSLPWGV-UHFFFAOYSA-N
SMILES :O.NCCNC(=O)c1ccc(Cl)cn1
安全情報
| 絵表示(GHS): |
|
|||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 注意喚起語: | Warning | |||||||||||||||||||||
| 危険有害性情報: |
|
|||||||||||||||||||||
| 注意書き: |
|
説明
Monoamine oxidases, MAO-A and MAO-B, regulate the intracellular concentrations of biogenic monoamines such as 5-hydroxytryptamine and dopamine via oxidative deamination. Inhibitors of MAO-A are widely used for the therapy of affective disorders, whereas MAO-B inhibitors have clinical efficacy in the treatment of Parkinson’s disease. Lazabemide is a reversible inhibitor of monoamine oxidase B (MAO-B) with IC50 values of 0.48 and 1.5 μM measured in platelets of human subjects ages 19-36 and 60-78, respectively. It is structurally similar to the MAO-B preferential substrate phenylethylamine and can be oxidized by MAO-B, forming tightly, but reversibly, bound adducts with the active site of the enzyme. The selectivity of lazabemide for MAO-B inhibition has been demonstrated in both in vitro and ex vivo conditions and it was evaluated in clinical trials for possible neuroprotective actions in the treatment of Parkinson’s disease.供給者とメーカー
3B Pharmachem (Wuhan) International Co.,Ltd.
LGM Pharma
BOC Sciences
Chengdu NoVi Biotechnology Co., Ltd.
Haoyuan Chemexpress Co., Ltd.
Finetech Industry Limited
Shanghai JiYi Biotechnology Co. Ltd.
Credit Asia Chemical Co., Ltd.
Guangzhou QiYun Biotechnology Co., Ltd.
Shanghai YuanYe Biotechnology Co., Ltd.